[20050308]RS21418_植物性药品监管.pdf

上传人:任我行 文档编号:17993 上传时间:2022-06-24 发布时间:2005-03-08 格式:PDF 页数:6 大小:42.34KB
下载 相关 举报
[20050308]RS21418_植物性药品监管.pdf_第1页
第1页 / 共6页
[20050308]RS21418_植物性药品监管.pdf_第2页
第2页 / 共6页
[20050308]RS21418_植物性药品监管.pdf_第3页
第3页 / 共6页
[20050308]RS21418_植物性药品监管.pdf_第4页
第4页 / 共6页
[20050308]RS21418_植物性药品监管.pdf_第5页
第5页 / 共6页
点击查看更多>>
资源描述

1、1 This sections sources include the Biotechnology Industry Organization, Pew Initiative on Foodand Biotechnology, and CRS Issue Brief IB10131, Agricultural Biotechnology: Overview andSelected Issues. Contacts: Tadlock Cowan (7-7600) on agricultural and USDA aspects of thisreport; Donna Vogt (7-7285)

2、 on medical, food safety, and Food and Drug Administration aspects.2 Personal communication with Legislative and Public Affairs Office, USDAs Animal and Plant(continued.)Congressional Research Service The Library of CongressCRS Report for CongressReceived through the CRS WebOrder Code RS21418Updated

3、 March 8, 2005Regulation of Plant-Based Pharmaceuticals Geoffrey S. BeckerResources, Science, and Industry DivisionDonna VogtDomestic Social Policy DivisionSummaryAmong many genetically engineered crops being developed are a number modifiedto produce pharmaceutical compounds (none yet commercialized

4、). Proponents say suchplant-based proteins could be produced more cheaply than by conventional methods andeconomically benefit farmers. But critics see risks, such as potential environmental,food safety, and trade problems. Among the issues is whether the current system forregulating biotechnology i

展开阅读全文
相关资源
猜你喜欢
相关搜索
资源标签

当前位置:首页 > 法规条令 > CRS 美国国会研究处报告